TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30710565

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the auricular branch of the vagus nerve (tVNS)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sham stimulation (earlobe)
Number of subjects: 97
Study: 29040124

Group type: EXPERIMENTAL
Intervention: XLPE liner (Marathon; DePuy)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional UHMWPE liner (Enduron; DePuy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 27339715

Group type: EXPERIMENTAL
Intervention: E-Coach intervention with condition-specific customization, in-hospital and post-discharge support by a care transition nurse, interactive voice response post-discharge calls, and CTN follow-up
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: E-Coach intervention
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual post-discharge care (UC)
Number of subjects: 511
Study: 24500308

Group type: EXPERIMENTAL
Intervention: Paricalcitol-centred therapy (IV and oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paricalcitol-centred therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cinacalcet-centred therapy
Number of subjects: 0
Study: 21790773

Group type: EXPERIMENTAL
Intervention: Baseline HbA(1c) values
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: HbA(1c) cut-off of 43 mmol/mol (6.05%)
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: HbA(1c) ≥ 48 mmol/mol (≥ 6.5%)
Number of subjects: 845
Study: 19669013

Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with 150 (1/4)g of clonidine (2 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with NS (2 mL)
Number of subjects: 30
Study: 16627543

Group type: EXPERIMENTAL
Intervention: 90Y and triamcinolone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intra-articular glucocorticoids alone (placebo and triamcinolone)
Number of subjects: 66
Study: 15592273

Group type: EXPERIMENTAL
Intervention: Inactive endometrium
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Proliferative endometrium
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Secretory endometrium
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Endometrial polyps
Number of subjects: 93
Study: 11288210

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine (0.5 mg of 0.1% solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nebulized salbutamol (2.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 30
Study: 9146453

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus incentives
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health risk assessment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Risk factor education
Number of subjects: 28
Study: 8196140

Group type: EXPERIMENTAL
Intervention: rhIL-1ra (100 mg loading dose followed by 1.0 or 2.0 mg/kg per hour continuous infusion)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: rhIL-1ra
Number of subjects: 893
Study: 3215873

Group type: EXPERIMENTAL
Intervention: High-intensity training (HI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-intensity training (LI)
Number of subjects: 17
Study: 30795802

Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab therapy
Number of subjects: 0
Study: 27861329

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite implant
Number of subjects: 281

Group type: COMPARATOR
Intervention: Acrylic implant
Number of subjects: 281
Study: 24946024

Group type: EXPERIMENTAL
Intervention: PS10 (IPAP 14 & EPAP 4 cm H2O)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PS0 (IPAP & EPAP 4 cm H2O)
Number of subjects: 10

Group type: COMPARATOR
Intervention: noPS (no ventilator)
Number of subjects: 10
Study: 23183315

Group type: EXPERIMENTAL
Intervention: Deception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misinformation
Number of subjects: 0
Study: 21996600

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 32
Study: 18470666

Group type: EXPERIMENTAL
Intervention: Exercise group (25 subjects)
Number of subjects: 50
Study: 15346340

Group type: EXPERIMENTAL
Intervention: Dryvax vaccination in previously vaccinated individuals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dryvax vaccination in vaccinia-naive individuals
Number of subjects: 30
Study: 12026534

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (hemodialysis and kidney transplantation)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) session
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Successful kidney transplantation and single HD session
Number of subjects: 89

Group type: COMPARATOR
Intervention: Erythropoietin treatment
Number of subjects: 89
Study: 9675631

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (performance contingent verbal feedback and planned interpersonal interaction in small groups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8008408

Group type: EXPERIMENTAL
Intervention: 24% sucrose
Number of subjects: 42

Group type: COMPARATOR
Intervention: Water
Number of subjects: 42
Study: 2683758

Group type: EXPERIMENTAL
Intervention: Anti-Tac monoclonal antibody (20 mg, administered intravenously daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (cyclosporine plus prednisone or cyclosporine plus azathioprine plus prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-Tac monoclonal antibody
Number of subjects: 0
Study: 1089438

Group type: EXPERIMENTAL
Intervention: Injection of phenol into the lumbar sympathetic chain
Number of subjects: 25

Group type: COMPARATOR
Intervention: Injection of local anaesthetic subcutaneously (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Treadmill testing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Calf blood pressure response following exercise
Number of subjects: 25
Study: 31177752

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3 g/day for 6 months
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Perilla oil (PO) 3 g/day for 6 months
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fish oil mixed with linseed oil (FLO) 3 g/day for 6 months
Number of subjects: 180
Study: 28486976

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with low-molecular-weight heparin (LMWH) at a dose of 85 IU/kg once daily during asparaginase courses of ALL treatment
Number of subjects: 324

Group type: COMPARATOR
Intervention: No thromboprophylaxis (standard of care) during asparaginase courses of ALL treatment
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with LMWH
Number of subjects: 324
Study: 25439084

Group type: EXPERIMENTAL
Intervention: Exercise + usual treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 50
Study: 22544420

Group type: EXPERIMENTAL
Intervention: Participatory training
Number of subjects: 3479

Group type: COMPARATOR
Intervention: Didactic training (control_1)
Number of subjects: 3479

Group type: COMPARATOR
Intervention: Didactic training (control_2)
Number of subjects: 3479
Study: 22097092

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fentanyl (1 microg kg(‐1))
Number of subjects: 60
Study: 19857084

Group type: EXPERIMENTAL
Intervention: GoChi (Lycium barbarum fruit juice) at 120 mL/day for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16707546

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study: 15546593

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over left DLPFC (12 sessions, alternate days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 11
Study: 11505341

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with 2 periods of 2‐minute ischemia followed by 3‐minute reperfusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stable control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unstable control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unstable IP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stable IP
Number of subjects: 80
Study: 9519518

Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 1014

Group type: COMPARATOR
Intervention: No leaflet (control)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Information leaflet (in patients treated with antibiotics)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: No leaflet (control, in patients treated with antibiotics)
Number of subjects: 1014
Study: 8287585

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naloxone (2.4 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile water (1 ml)
Number of subjects: 30
Study: 3816314

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol via inhalation aids (InspirEase, Aerochamber, Aerosol Bag)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albuterol aerosol via MDI mouthpiece
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo via inhalation aids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo via MDI mouthpiece
Number of subjects: 20
Study: 30114338

Group type: EXPERIMENTAL
Intervention: Visual linear scale (0% to 100%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnifier scale (after clicking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open-ended response mode
Number of subjects: 0
Study: 26767384

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (0.5 mg as eye drops for 10 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23886739

Group type: EXPERIMENTAL
Intervention: 66 mg/mL iodine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg/mL iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: >133 mg/mL iodine
Number of subjects: 0
Study: 21903969

Group type: EXPERIMENTAL
Intervention: Innovative sleeping device
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal sleeping device (control)
Number of subjects: 41
Study: 20433339

Group type: EXPERIMENTAL
Intervention: LSVT(R)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional dysarthria therapy (TRAD)
Number of subjects: 26
Study: 18458698

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg followed by 250 µg/(kg·min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study: 16148243

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (brief physician endorsement, handout, follow-up calls)
Number of subjects: 94
Study: 12011126

Group type: EXPERIMENTAL
Intervention: Epoetin beta 150 IU/kg
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 10443336

Group type: EXPERIMENTAL
Intervention: Soy milk supplement (1 litre daily for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rice dream (vegetable protein control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Semi-skimmed cow's milk (animal protein control)
Number of subjects: 10
Study: 8527268

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally with grapefruit juice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine 2.5 mg intravenously with grapefruit juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine 2.5 mg intravenously
Number of subjects: 16
Study: 2240630

Group type: EXPERIMENTAL
Intervention: Anesthetic regimen with nitrous oxide (N2O)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Anesthetic regimen without nitrous oxide (Control)
Number of subjects: 270
Study: 340305

Group type: EXPERIMENTAL
Intervention: Clomipramine (Anafranil) plus behaviour therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine plus simulated behaviour therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behaviour therapy alone
Number of subjects: 0
Study: 30570305

Group type: EXPERIMENTAL
Intervention: Mindfulness and prolonged chewing intervention (4 sessions)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 46
Study: 27502452

Group type: EXPERIMENTAL
Intervention: Platform-switching concept (abutment 3.8 mm in diameter)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard restoration (abutment 5.5 mm in diameter)
Number of subjects: 22
Study: 25245625

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg daily for 4 weeks
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for 8 weeks
Number of subjects: 408
Study: 22674565

Group type: EXPERIMENTAL
Intervention: Kouk Sun Do (KSD) exercise sessions (10 sessions, 70 minutes each, three times per week for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kouk Sun Do (KSD) exercise sessions
Number of subjects: 30
Study: 21756760

Group type: EXPERIMENTAL
Intervention: 3D‐Viewer system under a direct vision
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional operations
Number of subjects: 84
Study: 19130489

Group type: EXPERIMENTAL
Intervention: 20-week treatment trial
Number of subjects: 116
Study: 16867921

Group type: EXPERIMENTAL
Intervention: Women with dysthymia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Women with current depressive disorders
Number of subjects: 81

Group type: COMPARATOR
Intervention: Women without current depressive disorders
Number of subjects: 81
Study: 14758149

Group type: EXPERIMENTAL
Intervention: Red cells stored < or =5 days (10 patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Red cells stored > or =20 days (12 patients)
Number of subjects: 22
Study: 11059996

Group type: EXPERIMENTAL
Intervention: Intensive case management (ICM)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Standard case management (C)
Number of subjects: 545
Study: 11004136

Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling aiming for fat intake of 30% to 35% of daily energy, saturated/monounsaturated/polyunsaturated fatty acid ratio of 1:1:1, cholesterol intake of <200 mg/d
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1062
Study: 8968265

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 concentrations in women
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 concentrations in men
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transthyretin concentrations in women
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transthyretin concentrations in men
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Albumin concentrations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 108
Study: 1519481

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day for 28 days (open trial)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day (randomized trial)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN‐alpha) at doses of 3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day (randomized trial)
Number of subjects: 16
Study: 6507507

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose at home
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 100
Study: 29691233

Group type: EXPERIMENTAL
Intervention: 50 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 100 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 200 μmol oral BSE‐SFN daily for 28 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Plasma levels of proinflammatory cytokines
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tumor suppressor decorin
Number of subjects: 17
Study: 26708636

Group type: EXPERIMENTAL
Intervention: Single caffeinated energy shot
Number of subjects: 26

Group type: COMPARATOR
Intervention: Multiple caffeinated energy shots
Number of subjects: 26

Group type: COMPARATOR
Intervention: Caffeinated energy shots
Number of subjects: 26
Study: 24744162

Group type: COMPARATOR
Intervention: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 6 months (control group)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 18 months (study group)
Number of subjects: 1071
Study: 22172982

Group type: EXPERIMENTAL
Intervention: Concurrent visual task during text composition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard composition condition with written trace
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition with visual noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Condition with suppressed written trace
Number of subjects: 0
Study: 20451668

Group type: EXPERIMENTAL
Intervention: Continuation phase cognitive therapy (C-CT)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Fluoxetine (FLX)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 523
Study: 17400143

Group type: EXPERIMENTAL
Intervention: Prayer during surgery
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Relaxation technique during surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 78
Study: 15759292

Group type: EXPERIMENTAL
Intervention: (1)H NMR spectroscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other common bacteria (Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes, Acinetobacter baumanii, Proteus mirabilis, Citrobacter frundii, Enterococcus faecalis, Streptococcus gp B, Staphylococcus aureus)
Number of subjects: 30
Study: 12036817

Group type: EXPERIMENTAL
Intervention: 4 n‐3 fatty acid‐enriched egg yolks/wk
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 4 regular egg yolks/wk
Number of subjects: 161

Group type: COMPARATOR
Intervention: No dietary intervention
Number of subjects: 161
Study: 9572324

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study: 7626544

Group type: EXPERIMENTAL
Intervention: 65 deg, full depth-cue condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 65 deg, reduced depth-cue condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: Frontoparallel condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Holistic and multielement patterns
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 100 ms and 1 s exposures
Number of subjects: 64
Study: 2614884

Group type: EXPERIMENTAL
Intervention: ONO‐3708 (thromboxane A2 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30066672

Group type: EXPERIMENTAL
Intervention: SUPRAFLEX sirolimus‐eluting stent (SES)
Number of subjects: 1430

Group type: COMPARATOR
Intervention: XIENCE everolimus‐eluting stent (EES)
Number of subjects: 1430
Study: 30268481

Group type: EXPERIMENTAL
Intervention: Prognostic index (PI) lower than the signature median (n=92)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Prognostic index (PI) higher than the signature median (n=103)
Number of subjects: 195
Study: 26661723

Group type: EXPERIMENTAL
Intervention: Partial smoking ban
Number of subjects: 375

Group type: COMPARATOR
Intervention: No smoking ban
Number of subjects: 375
Study: 24751406

Group type: EXPERIMENTAL
Intervention: Dual-energy (DE) imaging
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single energy (SE) imaging
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional kV imaging
Number of subjects: 10
Study: 22064878

Group type: EXPERIMENTAL
Intervention: FATaintPHAT Web-based computer-tailored intervention
Number of subjects: 883

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 883
Study: 18615332

Group type: EXPERIMENTAL
Intervention: Betahistine 16 mg tid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Betahistine 24 mg bid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 17989709

Group type: EXPERIMENTAL
Intervention: Chemotherapy without stem cell transplant
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Patients <20 years old
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Patients >20 years old
Number of subjects: 1053
Study: 15950639

Group type: EXPERIMENTAL
Intervention: Single-dose (SD) protocol for GnRH antagonist (cetrorelix)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD) protocol for GnRH antagonist (cetrorelix)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long protocol (LP) for GnRH agonist (buserelin)
Number of subjects: 61
Study: 12131064

Group type: EXPERIMENTAL
Intervention: Multiple pain intensity measurements (average pain intensity measured 3 times a day over 4 days)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Single pain rating (recalled average pain as assessed by the patient)
Number of subjects: 54
Study: 10351969

Group type: EXPERIMENTAL
Intervention: TUNEL-positive myocytes in DCM specimens
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Percentage of TUNEL-positive myocytes per section in DCM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrastructural analysis of myocytes in DCM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Taq polymerase-based DNA in situ ligation assay
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expression of proliferating cell nuclear antigen in TUNEL-positive myocytes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expression of Ki-67 in TUNEL-positive myocytes
Number of subjects: 20